Idorsia Ltd (SWX: IDIA)
Switzerland
· Delayed Price · Currency is CHF
0.725
-0.034 (-4.48%)
Nov 19, 2024, 5:30 PM CET
Idorsia Revenue
Idorsia had revenue of 26.20M CHF in the quarter ending September 30, 2024, a decrease of -67.21%. This brings the company's revenue in the last twelve months to 74.12M, down -59.87% year-over-year. In the year 2023, Idorsia had annual revenue of 152.39M with 56.93% growth.
Revenue (ttm)
74.12M
Revenue Growth
-59.87%
P/S Ratio
1.75
Revenue / Employee
114.03K
Employees
650
Market Cap
136.07M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 60.58B |
Roche Holding AG | 60.58B |
Novartis AG | 42.18B |
Lonza Group AG | 6.70B |
Galderma Group AG | 3.88B |
Sonova Holding AG | 3.71B |
Straumann Holding AG | 2.54B |
Ypsomed Holding AG | 617.07M |
Idorsia News
- 6 days ago - Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension - PRNewsWire
- 9 days ago - Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions - GlobeNewsWire
- 2 months ago - Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 - GlobeNewsWire
- 2 months ago - Amended terms of Idorsia's 2024 convertible bonds become effective - GlobeNewsWire
- 4 months ago - Idorsia Ltd (IDRSF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call - GlobeNewsWire
- 5 months ago - Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension - GlobeNewsWire
- 5 months ago - Idorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality' category - GlobeNewsWire